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Abstract
Antibiotic-resistant pathogens represent an escalating threat to public health worldwide,
substantially increasing the burden of healthcare and community-acquired infections. Several
factors contribute to the emergence and spread of this threat, including but not limited to
improper antibiotic use and prescriptions in health-care settings and the community, increasing
global travel and migration from countries that have higher levels of antibiotic-resistant
pathogens, and a lack of new antibiotics under development. According to the World Health
Organization, rising rates of resistance among Gram-negative bacteria (such as Vibrio cholerae)
are of particular concern. These bacteria have evolved a number of endogenous membrane
remodeling strategies to sense and adapt to their environment. However, another membrane
remodeling strategy employed by these bacteria, the uptake and assimilation of exogenous longchain fatty acids, remains largely unexplored. Here, we seek to address this knowledge gap by
determining the extent to which phospholipid remodeling through uptake of exogenous PUFAs
impacts antimicrobial resistance in V. cholerae. As expected, resistance to polymyxin B is
substantially lower for mutants lacking the ability to modify LPS compared to the wild-type (El
Tor) strain. More interestingly, PMB resistance varies when cells are grown in the presence of
long-chain fatty acids. This difference is most noticeable for long-chain fatty acids abundant in
the human intestines.
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Introduction
Vibrio cholerae is a Gram-negative comma shaped bacterium that is associated with the
intestinal disease cholera. Each year there are an estimated 1.3 to 4.0 million cases of cholera,
and 21,000 to 143,000 of these cases end in death. The main treatment of cholera is immediate
administration of oral rehydration solution and antibiotics. There is also a traveler’s vaccine for
cholera that reports a 2-year protection [1]. Cholera is characterized with intense watery diarrhea
and severe dehydration. V. cholerae is found in brackish water and contaminated food.
Therefore, areas along the coast or those that without access to clean water are susceptible to
cholera outbreaks. Outbreaks are relatively rare in the industrialized world due to the advances in
public health and basic health care availability [2]. However, natural disasters can temporarily
disable these systems and create an environment where V. cholerae (Vc) can spread unchecked.
Outside of a human host, this bacterium can survive in bodies of water and marine animals, such
as oysters and crabs.
Because Vc is capable of surviving in drastically different environments, it can adapt to
its environment using numerous strategies. Perhaps the most effective of these is membrane
modification, wherein the bacterium will alter its membrane composition in response to a
stimulus, such as antimicrobial substances, immune system responses, or pH. Fatty acids present
in bile are involved in motility and virulence regulation as well as membrane modification. Left
untreated, V. cholerae will make its way to the small intestine. There it will interact with fatty
acids and antimicrobial peptides present in the small intestine [1]. In order to remain in the small
intestine, Vibrio will stick to the epithelial wall by forming a biofilm. Biofilm is an extracellular
matrix that bacteria use to stick to surfaces. Once the bacteria colony reaches a quorum, the
colony begins to produce cholera toxin (CT). Cholera toxin is comprised of A and B subunits.
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The B subunit binds to the epithelial cell via a GM1 receptor. The A subunit can then enter the
cell and enzymatically interact with G proteins. Multiple active G proteins lead to increased
cAMP levels and adenylyl cyclase activation [3, 4]. This series of events leads to a substantial
efflux of salt, water, and chlorine. This can very quickly spiral into dehydration and weakening
of the immune system.
V. cholerae outbreaks are well documented in history. These outbreaks were extremely
deadly due to a lack of sanitation. The more recent epidemics of Vc are thought to be spread by a
particular biotype: O1 El Tor. This strain is well adapted to survive in marine environments by
utilizing chitin as a carbon source [5]. The El Tor biotype differs by producing varying amounts
of cholera toxin and is capable of surviving in more stressful environments when compared to
the classical biotype. Also, this strain is more resistant to certain antibiotics. We hypothesize that
this resistance involves phospholipid modification, which would involve the inner leaflet of the
outer membrane, or the outer leaflet of the inner membrane. The aim of this project is to better
understand the effect of phospholipid modification on antimicrobial resistance.
Gram-negative bacteria possess two distinct membranes: an asymmetric outer membrane
composed of lipopolysaccharide (LPS) and phospholipids, and a symmetric inner membrane of
phospholipids. Conventional research focuses on outer membrane LPS as the critical barrier
against the environment. The LPS structure is composed of a bioactive lipid-A anchor, a core
oligosaccharide, and a long O-antigen chain. Another remodeling strategy employed by Vc, the
remodeling of phospholipid leaflets through the uptake and assimilation of long-chain fatty
acids, may also be important but remains poorly understood. This remodeling strategy is not
unique to Vc. Other pathogenic bacteria such as Acenitobacter baumanii, Klebsiella pnuemoniae,
and Pseudomonas aeruginosa have been shown to utilize exogenous long-chain fatty acids for
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membrane fortification [6-8]. However, Vc can incorporate larger fatty acids (20:5 and 22:6)
while other organisms, such as E. coli, struggle to incorporate fatty acids larger than 20 carbon
chains [9]. Previous research has assumed that the inner membrane functions primarily as a
passive homeostasis regulator of the cell and is not important for adapting to environmental
stressors. It has been demonstrated that Vc uptakes exogeneous long-chain fatty acids and
assimilates them into its membrane phospholipids. [4].
Of the range of PUFAs that Vc has demonstrated ability to uptake, we chose to focus on
those found in the human intestine or commonly associated with marine life. This study will
involve 4 total fatty acids, two of which are found in human intestines (18:2 and 20:4) and two
that are found in marine environments (20:5 and 22:6). Fatty acids are long carbon chains with a
carboxyl group at one end. Fatty acids present in these environments have been previously linked
to membrane phospholipid remodeling, permeability, and cascades related to fitness[10, 11]. Vc
is capable of transporting exogenous fatty acids through its outer membrane via FadL and then
transporting them through the periplasmic layer through unknown means [12]. The human
intestine is also rich in bile salts and antimicrobial peptides that are not present in marine life or
oceanic environments [4]. Current research links long-chain fatty acid uptake with changes in
cell permeability and membrane composition. Long-chain fatty acids are known to be heavily
involved in membrane modification and virulence regulation [3]. Virulence regulation is thought
to be linked to ToxT production. Certain long-chain fatty acids, such as 18:2, have been shown
to affect DNA binding of ToxT, which would result in lowering virulence and pathogenicity
[13]. Fatty acid concentrations are relatively high in bile and more specifically in the duodenal
lumen. ToxT production is significantly lower at these conditions. However, ToxT production
increases as long-chain fatty acid concentration decreases, which is similar to the conditions of
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the epithelial wall. Vc at these conditions produces biofilm, CT, and becomes pathogenic. What
is not well understood is the impact of long-chain fatty acid uptake on triggering certain stress
resistant cascades and if these modifications are derived from LPS modification or inner
membrane modification. Additionally, Vc. has been shown to break down these fatty acids using
acyl-CoA, a coenzyme for fatty acid metabolism. Acyl-CoA attaches to the long-chain fatty
acids to form fatty acyl-CoA esters which are then targeted for β-oxidation, phospholipid
synthesis through phosphatidic acid production, or transcriptional regulation [11, 12, 14]. We
aim to see if Vc is capable of using these long-chain fatty acids as an environmental marker for
membrane modification that results in antimicrobial peptide resistance among other relevant
phenotypes. This could help explain Vc’s proficiency in cycling between drastically different
environments and adapting to changes in pH, temperature, and salinity.
Cation antimicrobial peptides (CAMPs) are positively charged chains of amino acids that
are capable of binding to the LPS of Gram-negative bacteria. Polymyxin B is a highly selective
CAMP that can bind to the LPS at very specific places in order to disrupt the outer membrane.
Polymyxin B (PMB) bonds tightly to the LPS with orders of magnitude tighter than the
intramolecular forces that bind the lipid-A core together. Therefore, the ionic charge of the LPS
is displaced and this disrupts assembly of the outer membrane. PMB is also capable of crossing
the outer membrane and interfacing with the inner membrane. Here, PMB interacts with the
inner membrane to inhibit cellular energization which damages DNA replications and can result
in cell death [15]. V. cholerae El Tor is unique because of a recently discovered glycine
modification that is capable of reducing the overall negative charge of the outer membrane, thus
increasing its resistance to outer membrane disrupting CAMPs [16, 17]. A proposed model of
polymyxin B interaction is shown below in Figure 1 [15]:
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Figure 6: Polymyxin B Interaction with Inner and Outer Membrane
Polymyxin B is a cyclic cationic peptide that is soluble in aqueous environments. It was chosen
for this project due to its ability to disrupt the inner and outer membranes of Gram-negative
bacteria such as Vc.
Mutant strains of V. cholerae El Tor 1577 (AlmG) were provided by Dr. Giles from the
biology, geology, and environmental sciences department. The mutant strain used for this project
is unable to use the Alm-EFG operon for LPS modification. AlmF is transported across the inner
membrane to the outer bioactive LPS. Here it serves as a donor for AlmG to add a glycine or
diglycine group to LPS. This operon is not found in the classical biotype but is found in El Tor
[18]. Therefore, the mutant strain used in the below experiments (Vc 1577) is incapable of
adding a glycine or diglycine group to the LPS, which should therefore decrease resistance to
CAMPs. Many other operons are suggested to be involved in inner membrane modification or
antibiotic resistance, such as EptA and LpxR. However, the Alm-EFG variant was chosen due to
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its reliance on inner membrane modification and the parameters of the chosen experiments. A
suggested pathway for Alm-EFG outer membrane modification is shown below in Figure 7 [3,
19]:

Figure 7: Diglycine Modification of LPS Structure via Alm-EFG Operon
This research will advance our scientific understanding of how bacterial pathogens like
Vc use environmental markers to sense and adapt to stressors while cycling between host and
marine reservoirs. This could lead to novel yet simplistic preventative measures for dealing with
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bacterial pathogens, particularly those with increased resistance to antibiotics. It is possible that
this research could lead to the identification of new treatment methods and preventative
measures for Vc in addition to other pathogens that may rely on phospholipid membrane
fortification for stress response.

Methods
Vibrio cholerae C6706 El Tor and the mutant strain V. cholerae El Tor 1577 (AlmG)
were used throughout the experiments.
For liquid Luria broth (LB), 25 g of granulated LB was dissolved in 1 L of sterile DI
water. For LB agar plates, 25 g of granulated LB and 15 g agar are dissolved in 1 L of sterile DI
water. After autoclave sterilization, the solution is distributed among 50mm diameter Petri
dishes.
For M9 minimal media, (28.2) g of M9 salts and 20.67 g of NaCl are dissolved in sterile
DI water to make a 5x stock. Filter sterilized stock solutions stored include: 20% (w/v) glucose,
1M MgSO4, 1M CaCl2, and 20% casamino acids (CAAs).
For CM9 media, dilute 9ml of 5x M9 stock in 36ml of sterile DI water in a 50ml sterile
conical. Then add 450ul of previously made CAA, 900ul glucose, 4.5ul CaCl2, and 90ul of
MgSO4.
Antibiotic Resistance Assay
Antibiotic stock is made by dissolving 30 mg of PMB powder in 1 ml of sterile DI water.
1) Create 2 50 mL conicals of CM9 (*you will use a little more than 50mL per experiment day.)
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a) Use the sterile graduated cylinder to measure 9 mL of the 5x M9 + NaCl into two 50mL
conicals and add 36 mL of sterile water in each
i) This creates a total of 45mL 1x M9 with 150mM (37C) or 300mM (30C) NaCl
b) Add 450L filtered CAA to both conicals
c) Add 900L filtered glucose to both conicals
d) Add 9L filtered calcium chloride to both conicals
e) Add 90L filtered magnesium sulfate to both conicals
2) Use a blank with 1000𝑢𝐿 of DI Water to set the reference point, then remove overnight
cultures and record the ODs.
3) Pour 3 of the overnights into 2 15 mL conicals labeled ‘A1’ and ‘A2’ and spin for 10 mins at
4500 rpm.
a) While spinning, label 5 test tubes ‘-’, ‘18:2’, ’20:4’, ’20:5’, ’22:6’ and put 5 mL of the
CM9 (made in step 1) into each
4.) Once done spinning, pour off the supernatant and fill the 15 mL conicals with 1 mL CM9
and spin for 5 minutes at 4500 rpm
b) While spinning, retrieve FAs from black freezer downstairs and put 300mM in the
corresponding test tube
FATTY ACID

VOLUME (L)

18:2

0.54

20:4

1.83

20:5

1.83

22:6

1.97
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4) Once done spinning, pour off supernatants and re-suspend again in 1 mL in CM9
5) Break up the pellets and then take the OD of the two 15mL conicals.
6) Start the 5 labeled test tubes at an OD of 0.2 with the following equation:
(𝑐𝑢𝑙𝑡𝑢𝑟𝑒 𝑣𝑜𝑙𝑢𝑚𝑒)(𝜇𝐿) =

(𝑑𝑒𝑠𝑖𝑟𝑒𝑑 𝑂𝐷)(𝑡𝑜𝑡𝑎𝑙 𝑣𝑜𝑙𝑢𝑚𝑒)
(𝑐𝑢𝑙𝑡𝑢𝑟𝑒 𝑂𝐷)

∗ 1000

*remember to calculate culture from OD machine with an order of magnitude of 1.
Ex. Read 0.120 *apply order of magnitude of 1 gives* 1.20
7) Once solved for the equation add the calculated amount of culture to each of the 5 test tubes.
8) Place the 5 test tubes in the incubator shaking at 250 rpm at experimental temperature until
the OD has reached 6-8 (approx. 1.5 hours)

Antibiotic Resistance: Part 2
1) At 1.5 hours, take OD of control (should be 0.6-0.8)
2) Create the PMB dilutions in 1.5mL microcentrifuge low-bind tubes as follows:
Number

Dilution

Volume of PMB

Volume of CM9

stock (L)

(L)

1

0

0

500

2

40

4.5

495.5

3

80

9

491

4

160

18

482

5

320

35.5

464.5

6

640

71

429

7

1280

142

358

10
8

2560

284.5

215.5

3) Label the polypropylene 96-well microtiter plate as shown in the Appendix.
4) Add 30 L of each PMB dilution to the corresponding wells
a) Do this near the end of the growing period
5) Pour the 5 test tubes into 5 labeled 15mL conicals, balance the centrifuge, and spin for 10
minutes at 4500 rpm
a) While spinning, pipette 3.5 mL of CM9 into another set of 5 15mL conicals
6) Once done spinning, pour off the supernatant and fill the culture filled 15mL conicals with
growth with 1 mL CM9 and spin for 5 minutes at 4500 rpm
a) While spinning, retrieve FAs stored at -20°C and add 300 mM to the corresponding 15
mL conical

Fatty acid

Volume (L)

18:2

0.574

20:4

1.935

20:5

1.935

22:6

2.093

7) Once done spinning, pour off supernatant and resuspend in 1 mL of CM9
8) Break up the pellets and take the OD of the conicals
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9) Calculate the amount of culture needed to bring the conicals to an OD of 0.117/0.235(?)
according to the equation in step 7 of the antibiotic resistance part 1 procedure
a) Bring the total volume to 4.5 mL by subtracting this value from 1000 and adding this
amount of CM9 to each conical, using the table in the appendix to keep track of volumes
10) Add 170 L of each conical to the corresponding rows
11) Place the plate in the incubator, taped down and on top of a rack, shaking at 250 rpm

Reading the Antibiotic Plate
1) Remove the plate from the shaking incubator after 20 hours and use the microtiter plate
reader to read the plate at 600 nm
2) Ensure that no buildup has formed in the center of the well; if so, use a sterile pipette tip to
stir the contents of the well.

CFU Dilution Plate Assay
Antibiotic solutions are made by dissolving polymyxin B in CM9. The 10x stock concentrations
are as follows: Low (10ug/ml), Mid (100ug/ml) and High (200ug/ml).
CFU Dilution Assay:
1. Inoculate 2 tubes of 5ml LB and shake overnight at 250rpm and 37ºC.
2. After 16-20 hours, transfer the overnight culture into 15ml conical tubes and centrifuge
for 10 minutes at 4500 rpm.
3. Pour off the supernatant, being sure to not disturb the pelleted solids, and add 1ml of
CM9 to the two conical tubes.
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4. Put the conical tubes back in the centrifuge again for 10 minutes at 4500 rpm.
a. While spinning, label 4 test tubes ‘-’, ‘Low’, ’Mid’, ’High’, and put 4.5 mL of
CM9 into each tube.
b. For fatty trials, add 300mM of the desired fatty acids to each test tube
5. Pour off the supernatant and suspend in 1ml of CM9
6. Using the spectrophotometer, take the OD of 1000ul of DI water for a reference point.
7. Take the OD of each sample
8. Start the 4 labeled test tubes at an OD of 0.2 with the following equation:

𝑐𝑢𝑙𝑡𝑢𝑟𝑒 𝑣𝑜𝑙𝑢𝑚𝑒 (𝑢𝑙) =

𝐷𝑒𝑠𝑖𝑟𝑒𝑑 𝑂𝐷 ∗ 𝑇𝑜𝑡𝑎𝑙 𝑣𝑜𝑙𝑢𝑚𝑒 (𝑢𝑙)
∗ 1000
𝐶𝑢𝑙𝑡𝑢𝑟𝑒 𝑂𝐷

9. Add the calculated amount of culture to each test tube.
10. Add 500ul of 10ug/ml antibiotic stock to the test tube labelled ‘Low’, 500ul of the
100ug/ml antibiotic stock to the test tube labeled “Mid”, and 500ul of the 200ug/ml
antibiotic stock to the test tube labeled “High”. Add 500ul of CM9 to the test tube
labelled ‘-‘. This will create the desired antibiotic concentrations of 1ug/ml, 10ug/ml, and
20ug/ml for testing.
11. Place the 4 test tubes in the incubator shaking at 250 rpm at until the OD has reached 0.50.7 (approx. 2 hours)
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12. Set up 2ul microcentrifuge tubes and label them as shown below
-1

-2

-3

-4

-5

-6

L1

L2

L3

L4

L5

L6

M1

M2

M3

M4

M5

M6

H1

H2

H3

H4

H5

H6

13. Fill each microcentrifuge tubes with 900ul of sterile DI water
14. Pipette 100ul of “-” culture and add to the microcentrifuge tube labeled “-1”
15. Shake the microcentrifuge tube until well mixed, and then pipette 100ul of the diluted
mixture from “-1” into “-2”. Repeat this dilution 6 times, and for the 3 other cultures with
antibiotics.
16. Label two agar plates for each dilution (A and B).
17. Pipette 100ul of each dilution onto the appropriate two plates.
18. Submerge the cell spreader in 70% ethanol, flame it, and hold near the flame to dry.
19. Once cooled, apply a small amount of pressure and slowly spin the plate until an even
layer of culture is visible.
20. Repeat step 17 and 18 for each plate for all dilutions.
21. Wrap each plate in parafilm
22. Incubate for 24 hrs at 37 ºC.
23. Count the number of colonies on each plate. The plate is not relevant if the number of
colonies is below 30 or above 300.
24. Determine the number of colony forming units (CFU) by using the following formula
𝐶𝐹𝑈 = (# 𝑜𝑓 𝑐𝑜𝑙𝑜𝑛𝑖𝑒𝑠)(0.1) ∗ (10𝑛 )
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Where n is the dilution number.
25. To calculate percent survivability
𝑃𝑒𝑟𝑐𝑒𝑛𝑡 𝑠𝑢𝑟𝑣𝑖𝑣𝑎𝑏𝑖𝑙𝑖𝑡𝑦 =

𝐶𝐹𝑈 𝑒𝑥𝑝𝑒𝑟𝑖𝑚𝑒𝑛𝑡𝑎𝑙 𝑔𝑟𝑜𝑢𝑝
𝐶𝐹𝑈 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 𝑔𝑟𝑜𝑢𝑝

*100%

Where control group is defined as the group without exogenous fatty acids or
polymyxin B present.
OD600
Results and Discussion
All collected data was done with the help of Devin Martin and Konner Glass, fellow
undergraduate researchers working under Dr. Harris. The first method of testing polymyxin
involves serial dilutions across a 96 well plate. Sample data is shown below in Figure 8:

1.6
1.4

Absorbance (OD600)

1.2
1
18:2

0.8

20:4

0.6

20:5

22:6

0.4
0.2
0

0

200

400

600

800

1000

1200

1400

Polymyxin B (ug/mL)

Figure 8: Absorbance vs. Polymyxin B across Long-chain Fatty Acids
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Error bars represent a 95% confidence interval based on the Student’s t distribution. Low and
high concentrations (0-80 ug/ml and 1200 ug/ml) of polymyxin B resulted in large error bars
when compared to the 200-600ug/ml range. Although this method is capable of testing a large
range of antibiotic concentrations, we were unable to reproduce data consistently. Therefore, we
made the decision to pursue a different assay.
A CFU plate dilution was chosen to determine growth of Vc under these conditions.
Samples of Vc were grown with or without fatty acids. After an incubation period, aliquots of Vc
were plated using a cell spreader. After an overnight incubation, cells were counted, and percent
survivability was calculated. Percent survivability is a statistic that is based on the control, which
for our purposes was chosen to be the trial with no fatty acids or antibiotics present. Therefore,
percent survivability for the control will always be at 100%. A trial corresponding to a percent
survivability below 100% means that the trial grew less than a control trial. A trial corresponding
to a percent survivability above 100% means that the trial grew more than a control trial. It
should be noted that each trial was performed only once, in duplicate, due to time constraints.
Colony counts were averaged and then a CFU calculation was performed. Results for the wild
type (Vc El Tor) are shown below in Figure 9 and 5:
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Percent Survivabilty

100%
80%
control
60%

18:2
20:4

40%

20:5
22:6

20%
0%

Fatty Acid Present

Figure 9: Percent Survivability of Vc El Tor Wild-Type, without Polymyxin B added

Percent survivability of the 18:2, 20:4, and 22:6 trials were significantly lower than the control or
20:5 trial. 18:2 and 20:4 are found in the human intestine. Therefore, it can be interpreted that
fatty acids present in the human intestine hinder Vc’s ability to adapt to environmental stress
through an as yet unknown mechanism. Vc is capable of cycling between drastically different
environments. Therefore, long-chain fatty acids unique to each environment may be involved in
signaling cascades to combat stress. As previously mentioned, this could be due to a ToxT
operon interaction with these fatty acids. Vc has been shown to remodel its phospholipid layer to
combat membrane stress [6, 8]. Meanwhile, the reduction in survivability was noticeably less
pronounced for 20:5 and 22:6, which are omega-3 fatty acids commonly associated with marine
life. Taken collectively, these data can be construed to suggest that long-chain fatty acids play a
vital role in Vc’s ability to cycle between environmental niches.
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Antibiotics by their very nature are expected to inhibit growth. Minimum inhibitory
concentration (MIC) is the lowest concentration at which the antibiotic reduces growth of the
bacteria by at least 1 log. Polymyxin B at multiple concentrations (1ug/ml, 10ug/ml, 20ug/ml)
were used throughout the experimentation.

3.5%

Percent Survivability

3.0%
2.5%
Control

2.0%

18:2
1.5%

20:4
20:5

1.0%

22:6

0.5%
0.0%
1ug/ml

10ug/ml
Polymyxin B concentration

20ug/ml

Figure 10: Percent Survivability as a Function of PMB for Vc El Tor Wild-Type
Percent survivability is calculated by finding the CFU of a trial with an antibiotic, and dividing
by the control CFU (no antibiotic, no fatty acids present). In general, the fatty acid trials had
reduced resistance to antibiotics. 20:4 and 20:5 showed increased survivability for the 10ug/ml
trial and similar survivability for the 1ug/ml polymyxin B trial when compared to the control
group. This is interesting when compared to drastically initial growth of 20:4 as shown
previously in Figure 9. 20:5 also exhibited higher resistance to the 10ug/ml polymyxin B trial
when compared to the control group. Generally, 18:2 and 22:6 exhibited less growth and less
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resistance to antibiotic. The high antibiotic trial (20ug/ml polymyxin B) produced low percent
survivability across all trials.

The same experiment was performed using the Vc 1577 strain, an AlmG deficient mutant.
As previously stated, this strain is theoretically not capable of LPS modification that is relevant
for polymyxin B resistance. The mutant strain control group data is shown below in Figure 11
and Figure 12:

180%

160%
Percent Survivabilty

140%
120%

Control

100%

18:2

80%

20:4
20:5

60%

22:6

40%
20%
0%

Fatty Acid Present

Figure 11: Percent Survivability for Vc 1577 (ΔAlmG), without PMB added
The 20:5 trial produced a 167% percent survivability, meaning that the trial grew more
than the control group when polymyxin B is not present. It should be noted that the mutant
control group had a significantly higher CFU count when compared to the wild-type trial
(335500 vs. 197500). This could be due to the low amount of trials performed and the lack of
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statistical analysis due to time constraints. When compared to the wild-type experiments, 18:2
and 20:4 exhibited similarly low percent survivability. 22:6 has a drastically lower percent
survivability when compared to the wild-type experiments.

Percent Survivabilty

25%
20%
Control

15%

18:2
10%

20:4
20:5

5%

22:6

0%
1ug/ml

10ug/ml
Polymyxin B concentration

20ug/ml

Figure 12: Percent Survivability as a Function of PMB for Vc 1577 (ΔAlmG)
The control group (no fatty acid present) has a percent survivability of 1.78% at 1ug/ml
of polymyxin B, comparatively, the wild-type control group has a percent survivability of 2.93%.
The 20:5 trial has a percent survivability of 20.41%, which suggests that Vc is capable of using
20:5 as a carbon source for reproduction and/or to modify its membrane to resist polymyxin B.
The 10ug/ml polymyxin B trial has a 20:5 percent survivability of 1.01%, which is similar to the
relevant wild-type trial. 18:2 and 22:6 exhibited almost no growth when exposed to 1ug/ml of
polymyxin B, with percent survivabilities lower than 0.7%.
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Conclusion and Future Work
Vibrio cholerae is a Gram-negative bacterium that is responsible for at least 21,000
deaths every year. Long-chain fatty acids present in human and marine environments interact
with Vc’s membrane and influence virulence, membrane composition, and antibiotic resistance
[4, 12]. We suspect that Vc has evolved to uptake these long-chain fatty acids in order to cycle
through different environments. This would involve adapting to changes in temperature, salinity,
pH, and other stressors. Due to rising rates of antibiotic resistant pathogens, we chose to focus on
the influence of fatty acid availability on antibiotic resistance. Our initial focus was to use a 96well plate assay to test polymyxin B resistance for different fatty acids at a concentration of
350mM. However, due to unidentifiable issues, we were unable to reproduce data with
acceptable error bars. Therefore, we made the decision to change our assay to a CFU plate assay
which involves spreading serial dilutions on LB agar petri dishes, counting CFUs, and then
calculating percent survivability. In addition to the wild-type strain, we tested a mutant strain (Vc
1577) which has the AlmG gene silenced. This renders Vc unable to fortify its outer membrane
against CAMPs.
Interestingly, we found that the presence of 18:2 and 22:6 inhibited CAMP resistance for
both strains of Vc tested. Additionally, these fatty acids reduced growth when polymyxin B was
not present, while 20:4 and 20:5 had the opposite effect. They both had a neutral or positive
effect on growth with or without polymyxin B present. This is interesting because 20:4 is a
human fatty acid, and 20:5 is a marine environment fatty acid. Perhaps most surprising is that
22:6 had a negative effect on growth. This is a well-known carbon source for Gram-negative
bacteria. It should be noted that plating 22:6 trials was an onerous endeavor, with many trials
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ending in failure due to a lack of isolated colonies after overnight incubation. In light of this,
there could be an interaction taking place with 22:6 causing an undercount of CFUs.
The motivation of this project is to find a new strategy to combat antibiotic-resistant
microorganisms. The data collected throughout this project suggests that antibiotic resistance can
be directly affected by environment cues such as fatty acid concentration. We suggest that this
resistance is due in part to outer membrane modification through the uptake and utilization of
long-chain fatty acids. The mutant Vc experiments suggest that Alm-EFG is involved in
antibiotic resistance. However, the observed effect was not consistent across the range of fatty
acids tested. We hypothesize that Vc utilizes 20:5 in particular to fortify the inner leaflet of its
outer membrane, thereby conferring increased CAMP resistance. This hypothesis was formulated
based on the percent survivability results shown in Figure 12. Other studies report a polymyxin B
MIC of over 100ug/ml for Vc El Tor, and a MIC of 0.5-1.5 ug/ml for Alm-G mutants [3, 17].
Our data suggests a much lower MIC for Vc El Tor. Other studies rely on polymyxin B gradient
test strips to assess MIC and not the plating method used in this project. A plating based assay
was advantageous for this project due to the focus on comparing exogenous long-chain fatty acid
uptake on antimicrobial resistance. The future work for this project would begin with performing
each trial multiple times to attain statistical significance. It is unclear if any of the above data is
relevant due to the low number of trials performed. This method could also be repeated using
human defensins and other host-specific antimicrobial peptides. This would be vital for
understanding how Vc adapts to the host immune response. Lastly, future work would also
include evaluating a range of Vc mutants containing deletions to the outer membrane remodeling
machinery.
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Appendix

Table 1: Wild-Type CFU vs. Fatty Acid Present
Fatty Acid Present
Control
18:2
20:4
20:5
22:6

Colony Forming Units
197500
67000
5250
185500
100500

Table 2: Wild-Type CFU vs. Fatty Acid Present and Polymyxin B Concentration
Fatty Acid Present
Control
18:2
20:4
20:5
22:6

Polymyxin B Concentration
1ug/ml
10ug/ml
20ug/ml
5800
395
210
955
117
86
4600
3950
0
4300
1800
0
3150
0
0

Table 3: Vc 1577 CFU vs. Fatty Acid Present
Fatty Acid Present
Control
18:2
20:4
20:5
22:6

Colony Forming Units
335500
15500
36500
560000
18650
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Table 4: Vc 1577 CFU vs. Fatty Acid Present and Polymyxin B Concentration
Fatty Acid Present
Control
18:2
20:4
20:5
22:6

Polymyxin B Concentration
1ug/ml
10ug/ml
20ug/ml
6000
1125
77.5
27
4.5
0
2200
330
235
68500
3400
0
44
0
0

